Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for OptimizeRx (OPRX) over the last 15 years, with Q3 2025 value amounting to $2.0 million.

  • OptimizeRx's Share-based Compensation fell 2488.48% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year decrease of 2884.29%. This contributed to the annual value of $11.5 million for FY2024, which is 1640.3% down from last year.
  • OptimizeRx's Share-based Compensation amounted to $2.0 million in Q3 2025, which was down 2488.48% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, OptimizeRx's Share-based Compensation peaked at $4.4 million during Q1 2023, and registered a low of $582159.0 during Q1 2021.
  • Its 5-year average for Share-based Compensation is $2.7 million, with a median of $2.9 million in 2024.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 44522.87% in 2022, then plummeted by 4872.5% in 2025.
  • Over the past 5 years, OptimizeRx's Share-based Compensation (Quarter) stood at $3.1 million in 2021, then skyrocketed by 36.4% to $4.3 million in 2022, then tumbled by 38.47% to $2.6 million in 2023, then rose by 11.8% to $2.9 million in 2024, then plummeted by 33.4% to $2.0 million in 2025.
  • Its Share-based Compensation was $2.0 million in Q3 2025, compared to $1.5 million in Q2 2025 and $1.6 million in Q1 2025.